Patents Represented by Attorney, Agent or Law Firm Priscilla E. Porembski
  • Patent number: 6172189
    Abstract: The present invention provides unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: January 9, 2001
    Assignee: Abbott Laboratories
    Inventors: Sushil G. Devare, Suresh M. Desai, James M. Casey, Stephen H. Dailey, George J. Dawson, Robin A. Gutierrez, Richard R. Lesniewski, James L. Stewart, Kevin R. Rupprecht
  • Patent number: 6153377
    Abstract: The present invention provides a method of synthesizing genes encoding unique HIV-1 and HIV-2 envelope proteins and their fragments, thereby allowing overexpression of these proteins in E. coli. The HIV envelope proteins and their fragments have been expressed at high levels as individual proteins or in fusion with other proteins. The HIV envelope proteins thus expressed in E. coli can be effectively used for the detection of exposure to HIV as well as the discrimination of HIV-1 and HIV-2.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 28, 2000
    Assignee: Abbott Laboratories
    Inventors: Sushil G. Devare, James M. Casey, Suresh M. Desai
  • Patent number: 6150113
    Abstract: The invention is an improved immunoassay and method for detection of antibody to hepatitis B core antigen (anti-HBc). The improved assay comprises the addition of a reducing agent to decrease the number of false positive reactions in the assay.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: November 21, 2000
    Assignee: Abbott Laboratories
    Inventors: Richard H. Decker, John A. Weare
  • Patent number: 6001659
    Abstract: Chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compounds are disclosed in which the aryl group is poly-substituted with suitable electron-donating groups such that the light-emitting pattern of the molecule results in a very high luminescent count, thus providing for a sensitive and precise assay for haptens, analytes, polynucleotides and the like. These substituted aryl-containing 1,2-dioxetane compounds can be used as direct labels in an immunoassay or when derivatized with an appropriate leaving group, can be used as a substrate for a enzyme immunoassay. The unusual chemiluminescence of the compounds allows the timing of the luminescent reaction to be exactly controlled.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: December 14, 1999
    Assignee: Abbott Laboratories
    Inventors: Nai-Yi Wang, Roger C. Hu
  • Patent number: 6001561
    Abstract: Chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compounds are disclosed in which the aryl group is poly-substituted with suitable electron-donating groups such that the light-emitting pattern of the molecule results in a very high luminescent count, thus providing for a sensitive and precise assay for haptens, analytes, polynucleotides and the like. These substituted aryl-containing 1,2-dioxetane compounds can be used as direct labels in an immunoassay or when derivatized with an appropriate leaving group, can be used as a substrate for a enzyme immunoassay. The unusual chemiluminescence of the compounds allows the timing of the luminescent reaction to be exactly controlled.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: December 14, 1999
    Assignee: Abbott Laboratories
    Inventors: Nai-Yi Wang, Roger C. Hu
  • Patent number: 5955598
    Abstract: The present invention provides a method for quantitatively detecting the amount of a target nucleic acid sequence which may be present in a test sample. A test sample which may contain a target nucleic acid sequence comprising target sequences X and Y is contacted with two primer sets, the first set being specific for target X and the second set being specific for target Y. The test sample also is contacted at the same time with an internal standard sequence IS, which is substantially derived from a combination of the first and second target sequences, and its corresponding oligonucleotide primers. Haptens are associated with the oligonucleotide primer sets in such a way that amplified target sequence products X and Y are detected by capture on a solid phase to which anti-hapten capture reagents are attached. A signal ratio of (X+Y)/S is determined to quantitate the amount of the target nucleic acid sequence contained in the sample.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: September 21, 1999
    Assignee: Abbott Laboratories
    Inventors: Larry Birkenmeyer, Isa K. Mushahwar
  • Patent number: 5955318
    Abstract: Reagents and composition for controlling the translation of hepatitis GB virus (HGBV)-A, -B or -C peptides from viral nucleic acid. These reagents and methods comprise control elements of the 5' NTR region of the HGBV-A, -B, or -C viral genome.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: September 21, 1999
    Assignee: Abbott Laboratories
    Inventors: John N. Simons, Suresh M. Desai, Isa K. Mushahwar
  • Patent number: 5925512
    Abstract: Mutant Hepatitis B Virus (HBV) nucleic acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HBV nucleic acid sequences, HBV immunogenic particles, and a method for producing antibodies to HBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HBV nucleic acid sequences.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: July 20, 1999
    Assignee: Abbott Laboratories
    Inventors: William F. Carman, Richard H. Decker, Lesley Wallace, Larry T. Mimms, Larry R. Solomon
  • Patent number: 5895750
    Abstract: A biotin-antibiotin immunoassay comprises coating a solid phase with a ligand-specific binding material, reacting the solid phase with a test sample, reacting the solid phase with the biotin-labeled form of the ligand-specific binding material and antibiotin labeled with a suitable marker. The marker is then measured to detect the amount of ligand present in the test sample.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: April 20, 1999
    Assignee: Abbott Laboratories
    Inventors: Isa K. Mushahwar, Richard H. Decker, Karen V. Stuckmann
  • Patent number: 5859193
    Abstract: The present invention provides a method of synthesizing genes encoding unique HIV-1 and HIV-2 envelope proteins and their fragments, thereby allowing overexpression of these proteins in E. coli. The HIV envelope proteins and their fragments have been expressed at high levels as individual proteins or in fusion with other proteins. The HIV envelope proteins thus expressed in E. coli can be effectively used for the detection of exposure to HIV as well as the discrimination of HIV-1 and HIV-2.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: January 12, 1999
    Assignee: Abbott Laboratories
    Inventors: Sushil G. Devare, James M. Casey, Suresh M. Desai
  • Patent number: 5843450
    Abstract: Hepatitis GB Virus (HGBV) synthetic peptides useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV peptides.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: George J. Dawson, Tami J. Pilot-Matias, Dominique P. Bridon, Pamella A. Schroeder-Poliak, Mark F. Knigge, Keeve D. Jaffe, Isa K. Mushahwar
  • Patent number: 5830636
    Abstract: Monoclonal antibodies are described which specifically bind to Hepatitis E Virus (HEV), and more particularly to HEV orf-2 antigen. Also provided are hybridoma cell lines which secrete these monoclonal antibodies, methods for using these monoclonal antibodies, and assay kits which contain these monoclonal antibodies.
    Type: Grant
    Filed: February 22, 1996
    Date of Patent: November 3, 1998
    Assignee: Abbott Laboratories
    Inventors: Deborah A. Paul, Mark F. Knigge
  • Patent number: 5807670
    Abstract: HGBV-C oligonucleotides from the 5' end of HGBV-C useful for the detection and genotyping of HGBV-C isolates. Also provided are assays which utilize these oligonucleotides.
    Type: Grant
    Filed: December 21, 1995
    Date of Patent: September 15, 1998
    Assignee: Abbott Laboratories
    Inventors: Anthony Scott Muerhoff, John N. Simons, Thomas P. Leary, Larry Birkenmeyer, James C. Erker, Michelle Chalmers, George J. Dawson, Suresh M. Desai, Isa K. Mushahwar
  • Patent number: 5783699
    Abstract: Acridinium sulfonylamides and isomers, such as phenanthridinium sulfonylamides, may be employed in applications including chemiluminmescent immunoassays. Methods for synthesis of these compounds include contacting an amine with a sulfonylhalide to form a sulfonamide and acylating with an activated carboxylic acid of an acridine or isomer thereof. The N-sulfonyl-9-acridinium carboxamide and isomers may be conjugated to antigens, haptens, antibodies, and nucleic acids for use in chemiluminescent assays.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: July 21, 1998
    Assignee: Abbott Laboratories
    Inventors: Phillip Gregory Mattingly, Larry Gene Bennett
  • Patent number: 5753430
    Abstract: Monoclonal antibodies which specifically bind to either Hepatitis C Virus C-100 protein, Hepatitis C Virus 33C protein and Hepatitis C Virus CORE protein, and hybridomas which produce these monoclonal antibodies. Also provided are methods for using these monoclonal antibodies and assay kits containing these antibodies.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: May 19, 1998
    Assignee: Abbott Laboratories
    Inventors: Smriti U. Mehta, Jill Johnson, Sheela M. George, Suresh M. Desai, Larry T. Mimms, Sushil G. Devare, Joan D. Tyner, Mary S. Gibadlo
  • Patent number: 5709997
    Abstract: Nucleic oligomer probes useful for detection of HGBV in test samples. Also provided are assays which utilize these probes and test kits which contain these oligomer probes.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: January 20, 1998
    Assignee: Abbott Laboratories
    Inventors: Ronald L. Marshall, Cynthia Jou, John N. Simons, Thomas P. Leary, A. Scott Muerhoff, Suresh M. Desai, Isa K. Mushahwar
  • Patent number: 5681695
    Abstract: The invention is an improved immunoassay and method for detection of antibody to hepatitis B core antigen (anti-HBc). The improved assay comprises the addition of a reducing agent to decrease the number of false positive reactions in the assay.
    Type: Grant
    Filed: December 15, 1994
    Date of Patent: October 28, 1997
    Assignee: Abbott Laboratories
    Inventors: Richard H. Decker, John A. Weare
  • Patent number: 5669819
    Abstract: Acridinium sulfonylamides and isomers, such as phenanthridinium sulfonylamides, may be employed in applications including chemiluminmescent immunoassays. Methods for synthesis of these compounds include contacting an amine with a sulfonylhalide to form a sulfonamide and acylating with an activated carboxylic acid of an acridine or isomer thereof. The N-sulfonyl-9-acridinium carboxamide and isomers may be conjugated to antigens, haptens, antibodies, and nucleic acids for use in chemiluminescent assays.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: September 23, 1997
    Assignee: Abbott Laboratories
    Inventors: Phillip Gregory Mattingly, Larry Gene Bennett
  • Patent number: 5667966
    Abstract: Monoclonal antibodies are described which specifically bind to Hepatitis E Virus (HEV), and more particularly to HEV orf-3 antigen. Also provided are hybridoma cell lines which secrete these monoclonal antibodies, methods for using these monoclonal antibodies, and assay kits which contain these monoclonal antibodies.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: September 16, 1997
    Assignee: Abbott Laboratories
    Inventors: Deborah A. Paul, Mark F. Knigge
  • Patent number: 5667992
    Abstract: Mammalian expression systems for the production of HCV proteins. Such expression systems provide high yields of HCV proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 16, 1997
    Assignee: Abbott Laboratories
    Inventors: James M. Casey, Suzanne L. Bode, Billy J. Zeck, Julie Yamaguchi, Donald E. Frail, Suresh M. Desai, Sushil G. Devare